Metropolis Healthcare Limited
METROPOLIS · Hospitals · NSE
₹531
Current Market Price
Fair Value (DCF)
₹326
Discount to FV
-38.7%
Updated just now
YieldIQ Score
42/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
66%
ROE
12.6%
Debt/Equity
0.15
WACC
9.8%
Market Cap
₹11,003 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
23.9%
Return on capital employed
EV / EBITDA
29.6×
Enterprise multiple
Debt / EBITDA
0.6×
Leverage vs earnings
Interest Coverage
11.6×
EBIT covers interest
Current Ratio
1.40×
Short-term liquidity
Asset Turnover
0.77×
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.9%
3-year revenue growth
Revenue CAGR (5Y)
4.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹530.7
Bear case
Margin of Safety —
Implied upside -172.1%
Base case
Margin of Safety -170.5%
Implied upside -63.0%
Bull case
Margin of Safety -26.5%
Implied upside -20.9%
Ratio Trends
METROPOLIS · last 8 annual periods
ROE
12.6%
ROCE
23.9%
Operating Margin
—
Debt / Equity
0.15×
PE
45.3×
EV / EBITDA
22.0×
Historical Financials
METROPOLIS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1228 Cr | ₹1148 Cr | ₹1208 Cr | ₹1331 Cr | ₹1646 Cr | +7.6% |
| EBITDA | ₹376 Cr | ₹304 Cr | ₹292 Cr | ₹318 Cr | ₹417 Cr | +2.6% |
| EBIT | ₹313 Cr | ₹214 Cr | ₹197 Cr | — | — | -10.9% |
| PAT | ₹214 Cr | ₹143 Cr | ₹128 Cr | ₹145 Cr | ₹190 Cr | -2.9% |
| EPS (diluted) | ₹41.66 | ₹27.81 | ₹24.87 | — | — | -12.1% |
| CFO | ₹253 Cr | ₹247 Cr | ₹264 Cr | ₹263 Cr | ₹351 Cr | +8.5% |
| CapEx | ₹-30.7 Cr | ₹-52.6 Cr | ₹-63.8 Cr | ₹-68.6 Cr | ₹-51.2 Cr | — |
| FCF | ₹223 Cr | ₹194 Cr | ₹200 Cr | ₹194 Cr | ₹300 Cr | +7.7% |
| Total Assets | ₹1530 Cr | ₹1502 Cr | ₹1555 Cr | ₹1867 Cr | ₹2138 Cr | +8.7% |
| Total Debt | ₹379 Cr | ₹266 Cr | ₹197 Cr | ₹204 Cr | ₹232 Cr | -11.5% |
| Shareholders' Equity | ₹886 Cr | ₹988 Cr | ₹1096 Cr | ₹1331 Cr | ₹1513 Cr | +14.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
METROPOLIS vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 VIJAYA Vijaya Diagnostic Centre Limited | -455.6%-82.0% upside | 33 | Data Limited | 18.1% | — |
 THYROCARE THYROCARE TECH LTD | -5.6%-5.3% upside | 74 | Near Fair Value | 28.8% | — |
 SYNGENE Syngene International Limited | -81.5%-44.9% upside | 46 | Above Fair Value | 6.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
6 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹6.00/sh
Last payout
2025-11-11
₹1.00
Peak payout
₹2.00
Trailing yield
0.19%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Metropolis Healthcare Limited (METROPOLIS.NS) trades at 530.70 vs a model fair value of 325.51, a gap of -38.7%. Piotroski F-score: 5/9. ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of METROPOLIS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for METROPOLIS →
Compare
Head-to-head with peers
Compare METROPOLIS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse METROPOLISNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.